Merck & Co (MRK)

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a new multi-year cost-cutting initiative. The pharmaceutical giant posted total sales of $15.8 billion, representing a 2% decrease from the same period last year. This revenue shortfall was primarily driven by a steep 55% drop in sales for its Gardasil vaccine, which faced declining demand in China. While the company's earnings per share beat analysts' forecasts, investors appeared to focus on the top-line miss. Alongside the earnings, Merck announced a major restructuring plan aimed at saving $3 billion annually through measures that included layoffs and real estate reductions. The company stated these savings would be reinvested to support new product launches and its research pipeline.

Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64.8 billion at the midpoint. Its non-GAAP profit of $2.13 per share was 5% above analysts’ consensus estimates.

If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.

These big pharma stocks arguably aren't receiving the respect they deserve.

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.